SecBot SecBot

OKUR

OnKure Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001637715 Biotech & Drug Discovery
$2.49 −0.03 (−1.19%)
Oct 26 4:00 PM ET · prev $2.52
Market cap
$104.5M
Micro cap
Consensus
Buy
83% Buy or better · 12 analysts
Median target
$15.00
+502% · range $11.00–21.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.41
1 year
−30.3%
from $3.57 · Oct 27
30 days
−9.8%
from $2.76
52-week range
$2.10–5.27
−53% from high · low Oct 16
Avg volume 20D
455.0K
Oct 1 spike 2.08M
Short interest
1.22M
≈3.0% of shares · −11.0%
Days to cover
4.8
at average volume
Insider net
-$2.9K
0 buyers · 2 sellers · since Mar 31
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL Coastlands Capital LP filed a new Schedule 13G disclosing a 6.67% passive stake in OnKure Therapeutics…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $2.9K.

  • InstitutionsBULLISH

    Q2 2026: 16 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    10 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.573 → −$0.410 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −11.0% to 1.22M shares. 4.8 days to cover, ≈3.0% of shares.

  • TrendDOWNTREND

    18% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,499,845$6.8M
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED1,437,039$6.6M
CITADEL ADVISORS LLCDOUBLED1,187,047$5.4M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED724,438$3.3M
STATE STREET CORPDOUBLED463,662$2.1M
NORTHERN TRUST CORPDOUBLED197,177$899.1K
VANGUARD FIDUCIARY TRUST CODOUBLED165,177$753.2K
MARSHALL WACE, LLPDOUBLED159,881$729.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 83% rate it Buy or better
Strong Buy4Buy6Hold2Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +502%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 14, 2026Oppenheimer
REITERATE
REITERATEOutperform
Jul 20, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.9K
sold · 2 insiders
DateInsiderTypeValue
Sep 21, 2026
Leverone Jason A.
Chief Financial Officer
SELL$898.21
Sep 21, 2026
Saccomano Nicholas A
President and CEO
SELL$258.76
Aug 7, 2026
GREY MICHAEL G
Director
AWARD22,350 sh
Aug 7, 2026
Mathers Edward T
Director
AWARD22,350 sh
Aug 7, 2026
Ratcliffe Liam
Director
AWARD22,350 sh
Aug 7, 2026
Leverone Jason A.
Chief Financial Officer
TO ISSUER130,611 sh
Aug 7, 2026
Saccomano Nicholas A
President and CEO
AWARD150,000 sh
Aug 7, 2026
Manke Isaac
Director
TO ISSUER15,300 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.41
EPS estimate, this quarter
+28%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.41-$0.62–-$0.29+28.5%$125.0K
Next Q-$0.43-$0.67–-$0.30+27.5%$125.0K
Current FY-$1.83-$2.40–-$1.47+26.9%$250.0K
Next FY-$1.53-$2.08–-$1.15+28.3%$666.7K

Short side

FINRA· Sep 30, 2026
1,223,923
shares short
-11.0%
vs prior settlement
4.8
days to cover
≈3.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 7, 2026 SEC
Coastlands Capital LP filed a new Schedule 13G disclosing a 6.67% passive stake in OnKure Therapeutics, holding…
SC 13G — Impact 4/10
Sep 21, 2026 Insider
Leverone Jason A. sold 302 shares
Chief Financial Officer @ $2.97 ($898.21)
Sep 21, 2026 Insider
Saccomano Nicholas A sold 87 shares
President and CEO @ $2.97 ($258.76)
Aug 31, 2026 Other
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinic
Aug 7, 2026 Insider
GREY MICHAEL G was granted 22,350 shares
Director
Aug 4, 2026 SEC
OnKure Therapeutics reported Q2 2026 net loss of $15.3M ($0.31/share) vs $15.4M ($1.14/share) in Q2 2025, with the…
8-K — Impact 4/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
1,499,845 shares ($6.8M)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — DOUBLED
1,437,039 shares ($6.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
OKUR Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Aug 31, 2026
Press release
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on…
Aug 31, 2026
Short interest
Short Interest: OKUR up 23% to 1.3M shares
Settlement 2026-08-31 | Days to cover: 7.70 | ≈3.26% of shares outstanding (est.)
Aug 4, 2026
Earnings
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular…
Jul 15, 2026
Short interest
Short Interest: OKUR up 34% to 1.2M shares
Settlement 2026-07-15 | Days to cover: 5.79 | ≈2.93% of shares outstanding (est.)
Jul 2, 2026
Press release
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on…

SecBot reports

5 filings · 1 press release · 0 bullish · 1 bearish · 4 neutral
All OKUR filing & press-release reports (6)